The primary goal of modern drug research and development is to screen, determine and prepare effective drug targets. CRISPR-Cas9 can efficiently and precisely edit genes in multiple types of cells and tissues. According to the most recent literature, gene editing technology based on the CRISPR-Cas9 present great potential and prospect for the application in a series of drug targets screening.
By constructing a sgRNA library, Synbio Technologies can use lentivirus-transfected cells to screen the large-scale protein and its domain, all of which can play an important role in the process of disease occurrence and maintaining the cancer cell growth, survival, and development. Moreover, we can then combine this with NGS and data analysis, which is especially important for finding the right drug targets and developing new drugs, especially cancer treatments.
Advantages of Screening Services for Research & Development of New Drugs
- One-stop Service
- Patented Next Generation Gene Synthesis Platform
- High Throughput Screening Platform
- Biological Information Analysis
Synbio Technologies provides an integrated solution for sgRNA design, sgRNA library construction, lentivirus packaging, target screening and subsequent verification.
High-throughput and low-cost sgRNA library construction based on the chip- synthesis technology, the coverage of constructed library is more than 95%.
Synbio Technologies can offer a whole genome library screening and parallel analysis of gene functions of a large number of cells, including cell viability, proliferation, apoptosis and other phenotype detection. It can also identify relevant candidate genes.
Experienced bioinformatics analysis team, robust technical support, and in-depth analysis of NGS data to precisely select target candidate genes.
 Parnas, O., et al., A Genome-wide CRISPR Screen in Primary Immune Cells to Dissect Regulatory Networks. Cell, 2015. 162(3): p. 675-86.
 Sanjana, N.E., Genome-scale CRISPR pooled screens. Anal Biochem, 2016.
 Varshney, G.K., et al., A high-throughput functional genomics workflow based on CRISPR/Cas9-mediated targeted mutagenesis in zebrafish. Nat Protoc,2016. 11(12): p. 2357-2375.